Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 29 2024
0mins
Source: NASDAQ.COM
Company Performance: Vertex Pharmaceuticals has shown strong stock performance, gaining 32.7% over the past year, outperforming both the S&P 500 and the VanEck Biotech ETF, driven by successful product launches and anticipated FDA decisions.
Analyst Ratings and Forecasts: The consensus among analysts is a "Moderate Buy" for VRTX, with a mean price target of $520.48, indicating potential upside, while RBC Capital maintains a "Hold" rating with a price target of $451.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 515.88 USD with a low forecast of 414.00 USD and a high forecast of 604.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 461.140
Low
414.00
Averages
515.88
High
604.00
Current: 461.140
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
